APTENSIO XR Drug Patent Profile

Which patents cover Aptensio Xr, and when can generic versions of Aptensio Xr launch?

Aptensio Xr is a drug marketed by Rhodes Pharms and is included in one NDA.

The generic ingredient in APTENSIO XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aptensio Xr

A generic version of APTENSIO XR was approved as methylphenidate hydrochloride by SPECGX LLC on November 27^th, 1998.

Summary for APTENSIO XR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	53
Clinical Trials:	4
Patent Applications:	4,201
Drug Prices:	Drug price information for APTENSIO XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for APTENSIO XR
What excipients (inactive ingredients) are in APTENSIO XR?	APTENSIO XR excipients list
DailyMed Link:	APTENSIO XR at DailyMed

See drug prices for APTENSIO XR

Recent Clinical Trials for APTENSIO XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Matthew J O'Brien, PhD, BCBA-D	Phase 4
Matthew O'Brien	Phase 4
Rhodes Pharmaceuticals, L.P.	Phase 4

See all APTENSIO XR clinical trials

Pharmacology for APTENSIO XR

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for APTENSIO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
APTENSIO XR	Extended-release Capsules	methylphenidate hydrochloride	30 mg	205831	1	2016-03-28
APTENSIO XR	Extended-release Capsules	methylphenidate hydrochloride	15 mg, 20 mg, 40 mg and 50 mg	205831	1	2015-12-28
APTENSIO XR	Extended-release Capsules	methylphenidate hydrochloride	10 mg	205831	1	2015-12-24
APTENSIO XR	Extended-release Capsules	methylphenidate hydrochloride	60 mg	205831	1	2015-12-23

US Patents and Regulatory Information for APTENSIO XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-001	Apr 17, 2015	AB3	RX	Yes	No
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-007	Apr 17, 2015	AB3	RX	Yes	Yes
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-004	Apr 17, 2015	AB3	RX	Yes	No
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-002	Apr 17, 2015	AB3	RX	Yes	No
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-003	Apr 17, 2015	AB3	RX	Yes	No

Expired US Patents for APTENSIO XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-001	Apr 17, 2015
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-006	Apr 17, 2015
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-002	Apr 17, 2015
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-005	Apr 17, 2015
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-004	Apr 17, 2015

International Patents for APTENSIO XR

See the table below for patents covering APTENSIO XR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1140088	FORMULATIONS ORALES DE METHYLPHENIDATE A LIBERATION REGULEE/MODIFIEE (CONTROLLED/MODIFIED RELEASE ORAL METHYLPHENIDATE FORMULATIONS)
European Patent Office	1143937	FORMULATIONS A LIBERATION CONTROLEE CARACTERISEES PAR UNE ACTION IMMEDIATE ET UNE DIMINUTION RAPIDE DES CONCENTRATIONS EFFICACES DE MEDICAMENTS DANS LE PLASMA (CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS)
Japan	2007119479	CONTROLLED/MODIFIED RELEASE TYPE METHYLPHENIDATE ORAL PREPARATION
Hong Kong	1124257
Austria	268595

Market Dynamics and Financial Trajectory for APTENSIO XR

Last updated: January 5, 2026

Executive Summary

APTENSIO XR (methylphenidate hydrochloride extended-release) is a prescription medication approved by the FDA primarily for Attention Deficit Hyperactivity Disorder (ADHD) in children and adults. Released by Elan Pharmaceuticals (now part of Arbor Pharmaceuticals), it faces a competitive landscape rooted in stimulant-based therapies. This analysis explores the drug’s market positioning, recent financial performance, key drivers, challenges, and future trends. Currently, the ADHD pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of approximately 6.4% until 2028, driven by increased diagnosis rates and unmet needs in certain populations [1].

---

What Are the Market Dynamics Influencing APTENSIO XR?

1. Competitive Landscape

APTENSIO XR operates within a high-growth segment with numerous rivals, including:

Competitors	Key Products	Market Share (Est.)	Strengths	Weaknesses
Concerta (J&J)	Methylphenidate ER	40-45%	Established brand, extensive data	Higher cost, once-daily dosing
Adderall XR (Shire/AbbVie)	Amphetamine salts ER	25-30%	Well-known, multiple formulations	Abuse potential, side effects
Vyvanse (Shire)	Lisdexamfetamine	15-20%	Lower abuse potential, convenient dosing	Higher price point
Focalin XR (Novartis)	Dexmethylphenidate ER	5-8%	Shorter onset, alternative option	Limited geographic reach

Note: Market share figures are approximations, derived from IMS data (2022) and industry reports.

Market Entry and Patent Considerations

• Patent expirations for leading methylphenidate formulations, such as Concerta (expiration in 2030), influence market share shifts.
• Orphan and specialty drug status may provide competitive advantages or limitations.

2. Regulatory and Reimbursement Environment

• FDA approval pathways for AB-rated generics are crucial; generics dominate pricing and prescribing habits.
• Insurance reimbursement policies favor generics, giving branded drugs like APTENSIO XR a competitive disadvantage unless value propositions are demonstrated.
• Pricing Trends: The average wholesale price (AWP) for APTENSIO XR ranges between $200–$250 per month, roughly aligned with branded stimulant medications.

3. Key Market Drivers

Driver	Impact	Data/Source
Rising ADHD Diagnosis	US prevalence in children increased from ~9.4% (2016) to ~10.2% (2021)	CDC [2]
Increased Awareness and Stigma Reduction	Greater willingness to seek treatment	CDC, NIMH [3]
Treatment Guidelines	Favor extended-release formulations for adherence and abuse deterrence	AAP Guidelines [4]
Physician Prescribing Trends	Shift towards branded, long-acting stimulants	IQVIA [5]
Product Differentiation	Unique release technology and dosing flexibility	Arbor Pharmaceuticals data

---

Financial Trajectory: Past, Present, and Future

1. Historical Performance

• Initial Launch (2016-2018):
  • APTENSIO XR exhibited modest growth, accruing less than 1% share in the methylphenidate segment.
  • Marketing efforts focused on pediatric prescribing populations.
• Key Financials (2020-2022):
  • Revenue: Estimated at $50 million in 2022, on a growth trajectory of approximately 20% YoY.
  • Market Penetration: Growing prescriber acceptance; increased awareness among healthcare providers.
  • Profitability: Assumed breakeven or marginal profit; detailed margins are not publicly disclosed.

2. Current Financial Status

Metric	2022 Estimation	Notes
Total Revenue	~$50 million	Reflects increased market acceptance
Market Share	Approx. 2–3%	In the methylphenidate ER segment
Sales Growth	20% YoY	Driven by expanding prescriber base and formulary access
Pricing	$200–$250/month	Slight premium over generic methylphenidate formulations

3. Future Projections (2023-2028)

Year	Projected Revenue	Compound Growth Rate	Assumptions
2023	~$60 million	20%	Continued prescriber uptake, formulary wins
2024	~$72 million	20%	Additional indications, market expansion
2025	~$86 million	20%	Increased generic competition, premium positioning
2026	~$103 million	20%	Market saturation, new formulation launches
2027	~$124 million	20%	Expand into adult ADHD segment
2028	~$149 million	20%	Potential new dosing forms, international expansion

---

Key Factors Impacting Financial Outcomes

Factor	Effect	Strategic Response
Generic Competition	May pressure prices and market share	Differentiation, formulary positioning, patent litigations
Regulatory Changes	Potential restrictions or incentivization for specific formulations	Monitoring FDA policies and engaging in policy advocacy
Accumulation of Data and Real-World Evidence	Supports efficacy and safety claims, enhances prescriber confidence	Investment in clinical data generation
Market Expansion (International)	Growth opportunities outside the US	Regulatory navigation, partnerships with global pharma markets
Pricing and Reimbursement Trends	Influences accessibility and adoption	Strategic pricing, value-based agreements

---

Comparative Analysis with Similar Drugs

Aspect	APTENSIO XR	Concerta	Vyvanse	Adderall XR
Active Ingredient	Methylphenidate ER	Methylphenidate ER	Lisdexamfetamine	Mixed amphetamine salts
Release Technology	Multi-layered bead	Osmotic pump	Prodrug	Mixed salts
Dosing Flexibility	Multiple formulations	Once daily	Once daily	Once daily
Approval Year	2015	2000	2007	1996
Pricing (Approx.)	$200–$250/month	$250–$300/month	$250–$300/month	$150–$200/month
Market Share (Estimate)	2–3%	40–45%	15–20%	25–30%

---

Challenges and Risks

Challenge/Risk	Impact	Mitigation Strategies
Generic Competition	Price erosion, market share loss	Focus on formulation innovation, patent strategies
Pricing Pressure	Revenue dilution	Demonstrate added value through clinical outcomes, payer negotiations
Regulatory Changes	Potential restrictions on marketing or formulation modifications	Active engagement with regulators, adaptive formulation strategies
Market Saturation	Limited growth in mature markets	International expansion, new indications
Supply Chain Disruptions	Manufacturing delays, stockouts	Diversify production and supply sources

---

Future Trends and Opportunities

• Innovative Formulations: Development of alternative delivery systems, such as transdermal patches or once-yearly injections, could differentiate APTENSIO XR.
• Expanding Indications: Potential use in narcolepsy or binge-eating disorder may present new revenue streams.
• Digital Health Integration: Incorporating digital adherence tools to improve patient outcomes.
• Global Expansion: Navigating regulatory pathways in Europe, Asia, and emerging markets.

---

Key Takeaways

1. Market Positioning: APTENSIO XR maintains a niche among methylphenidate extended-release therapies, facing stiff competition but benefiting from formulation advantages.
2. Financial Outlook: Expected to grow at approximately 20% annually through 2028, driven by increased ADHD prevalence and prescriber acceptance.
3. Competitive Challenges: Patent expiries and generics pose risks; innovation and strategic positioning remain critical.
4. Strategic Opportunities: Product differentiation, new formulations, international markets, and expanding indications can enhance long-term growth.
5. Market Dynamics: Trends in diagnosis, treatment preferences, and healthcare policies will shape future trajectories.

---

FAQs

1. How does APTENSIO XR compare to other ADHD medications?

APTENSIO XR offers unique multi-layered bead technology that allows for flexible dosing and potentially smoother pharmacokinetics. Compared to traditional methylphenidate formulations like Concerta, it may provide better tolerability or adherence but faces similar pricing and market challenges.

2. What are the primary risks to APTENSIO XR’s market growth?

Key risks include increasing generic competition, pricing pressures, regulatory hurdles, and saturation in the established markets. Patent expirations threaten market exclusivity, potentially leading to reduced margins.

3. What growth channels are available for APTENSIO XR?

Expansion into adult ADHD populations, international markets, and exploring alternative delivery forms are promising; also, demonstrating superior outcomes through real-world evidence can foster wider adoption.

4. How does reimbursement policy influence APTENSIO XR’s sales?

Favorability of formulary placement hinges on cost-effectiveness and clinical differentiation. Payer negotiations are crucial for ensuring patient access and pricing sustainability.

5. What is the outlook for new formulations or indications?

Innovation in delivery systems (e.g., patches, implants) and exploring indications beyond ADHD could provide substantial growth, although regulatory pathways and clinical validation are required.

---

References

[1] Market Research Future, "Global ADHD Drugs Market," 2022.
[2] CDC, "Prevalence of ADHD", 2021.
[3] NIMH, "ADHD in Children and Adults," 2022.
[4] American Academy of Pediatrics, "Updated Guidelines for ADHD," 2019.
[5] IQVIA, "Pharmaceutical Market Reports," 2022.